GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
Dr. Karen Kelly: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Karen Kelly, of the University of California, Davis, reviews ...
Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
-
HD
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (video)
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data ...
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.
-
HD
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (audio)
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data ...
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.
-
HD
GRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology, Canada
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective ...
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
-
HD
Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread ...
Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread availability of new mutation tests under the Canadian health care system.
-
HD
Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"
Dr. Sarah Goldberg from Yale Cancer Center describes which molecular ...
Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.
-
HD
Dr. Heather Wakelee on "My Approach to Maintenance Therapy for Advanced NSCLC"
Dr. Heather Wakelee, from Stanford University, discusses the evidence and ...
Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
-
HD
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (video)
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early ...
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).
-
HD
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early ...
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).
-
HD
Dr. Sumanta (Monty) Pal: What Are the Options for Second Line Treatment of Kidney Cancer?
Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope ...
Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to second line treatment of kidney cancer.
